Collplant ADR earnings beat by $0.56, revenue fell short of estimates
Collplant ADR (CLGN) reported Q3 EPS of -$1.89, beating estimates by $0.56, but revenue of $108K missed expectations of $480K. The stock is up 11.11% in 3 months but down 84.63% in 12 months. InvestingPro rates its financial health as 'weak performance'.
How this was made
The 30-second read
Why it matters
The earnings surprise may trigger a brief rally, but investors will likely await guidance or pipeline updates to gauge longer‑term prospects.
Market read
Earnings release provides fresh data for a micro‑cap biotech, offering limited but actionable insight for short‑term traders.
What to watch
Potential upcoming clinical trial data or partnership announcements could change the narrative beyond the earnings numbers.
Background
Collplant ADR (NASDAQ: CLGN) is a biotech firm developing plant‑based protein therapeutics. The company posted a surprise EPS beat but a significant revenue shortfall for Q3 2026.
Ticker impact
Collplant ADR reported Q3 EPS of $-1.89, beating estimates by $0.56, with revenue of $108K versus $480K consensus.
modest upside as market prices in the EPS beat, tempered by revenue shortfall
The surprise EPS beat is a positive catalyst, yet the large revenue miss suggests mixed fundamentals, leading to limited price movement.
Market effects
Highlights ongoing volatility in the biotech/plant‑based therapeutics sector, where earnings beats are often offset by revenue concerns.
Limited to U.S. ADR investors; no broader regional effect.
Low, as the company is a micro‑cap with niche focus.
Counterpoint
Revenue miss may signal deeper demand issues; short sellers could target the stock despite the EPS beat.
Key entities
- companyCollplant ADR
Biotech firm focused on plant‑based therapeutics, ticker CLGN.
